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Abstract
Background: Cis-planaramineplatinum(II) complexes like their trans isomers are often found to be
active against cancer cell lines. The present study deals with the synthesis, characterization and
determination of activity of new cis-planaramineplatinum(II) complexes.
Results:  Two  cis-planaramineplatinum(II) complexes: cis-(3-
hydroxypyridine)(ammine)dichloroplatinum(II) (code named AH3) and cis-(2,3-
diaminopyridine)(ammine)dichloroplatinum(II)  (code named AH7) have been prepared and
characterised based on elemental analyses, IR, Raman, mass and 1H NMR spectral measurements.
The interactions of the compounds with pBR322 plasmid DNA have been investigated and their
activity against ovarian cancer cell lines: A2780, A2780cisR and A2780ZD047Rhave been determined.
Like cisplatin, AH3 and AH7 are believed to form mainly monofunctional N7(G) and bifunctional
intrastrand N7(G)N7(G) adducts with DNA, causing a local distortion of a DNA strand. As a result,
gel mobility of the DNA changes. Both AH3 and AH7 are found to be less active than cisplatin
against the three cell lines with AH3 being the more active compound of the two. The higher
activity of AH3 is in line with its lower molar conductivity value corresponding to a lower degree
of dissociation.
Conclusion: The differences in activity of AH3, AH7 and cisplatin against the cell lines illustrate
structure-activity relationship.
Background
Although cisplatin is a widely used anticancer drug [1,2],
it has a number of side effects and a limited spectrum of
activity [3-7]. In an attempt to reduce toxicity and widen
the spectrum of activity thousands of cisplatin analogues
have been prepared by varying the nature of the leaving
groups and the carrier ligands [8]. By manipulating the
structure the leaving groups it has been possible to reduce
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toxicity (eg substitution of the more stable cyclobutanedi-
carboxylate for the two chlorides led to the development
of carboplatin which produces substantially less nausea,
vomiting and neurotoxicity but causes more of myelosup-
pression) and that of the carrier ligands, it has been possi-
ble to achieve a limited change in the spectrum of activity
(eg oxaliplatin which has 1,2-diaminocyclohexane as the
carrier ligands has been found to be active against color-
ectal cancer whilst cisplatin is not) [9-11]. In spite of the
progress made, it is generally true to say that all cisplatin
analogues have a similar spectrum of activity and develop
cross resistance with cisplatin [8].
Currently attention is given to rule breaker platinum com-
pounds with the idea that different nature of interaction
with DNA may translate into a different spectrum of activ-
ity. One such class of compounds are trans-planara-
mineplatinum(II) complexes a number of which have
been found to be quite active against both cisplatin-
responsive and cisplatin-resistant cancer cell lines [12].
Often it is found that the cis-isomers of the compounds
are also active. For example, ZD0D473 has been found to
show significant antitumour activity against a number of
cancer cell lines [13].
In our laboratory a number of trans-planaramineplati-
num(II) complexes of the form: trans-PtCl2NH3L (L = 2-
hydroxypyridine, 3-hydroxypyridine, imidazo [1,2-
α]pyridine) have been prepared which have shown signif-
icant anticancer activity [14,15]. One of the compounds is
twice as active as cisplatin against A2780cisR cell line. The
variations in activity of the compounds and conforma-
tional changes induced in pBR322 plasmid DNA illustrate
structure-activity relationship. Later we reported on the
synthesis and activity of some cis-planaramineplati-
num(II) complexes as well [16]. In this paper, we report
on the synthesis, binding with DNA and activity of two
cis-planaramineplatinum(II) complexes of the form: cis-
PtL(NH3)Cl2 where L = 3-hydroxypyridine and 2,3-diami-
nopyridine (Figure 1). Both the compounds are found to
be less active than cisplatin against three ovarian cancer
cell lines: A2780, A2780cisR and A2780ZD047R.
Results and discussion
Characterisation
The compositions of AH3 and AH7 are given in Table 1.
Significant difference between calculated and observed
carbon contents for AH3 indicates that the compound
contains some impurity possibly cis-bis(3-hydroxypyrid-
ine)dichloroplatinum(II).
Molar conductivity
Figure 2 gives plots of molar conductivities against con-
centrations as applied to AH3, AH7, cisplatin and transpl-
atin.
The limiting values of molar conductivity (in ohm-1 cm2
mol-1) at zero concentration of AH3 and AH7 were found
to be 150 and 210 respectively as against 200 for cisplatin
and 150 for transplatin. These values are significantly
lower than the expected value of about 280 for a 1:2 elec-
trolyte, indicating that the degree of dissociation is about
54% in the case of AH3 and 75% in the case of AH7. The
results suggest that AH3 may be crossing the cell mem-
brane more readily than AH7 by passive diffusion. Since
the degree of dissociation is significant, both the mole-
cules may be crossing the cell membrane also by carrier-
mediated transport (more so for AH7 than AH3). The
lower molar conductivity values of AH3 and AH7 as com-
pared to cisplatin suggests that the degree of dissociation
of the compounds is less than that for cisplatin. This is in
line with the presence of a bulkier planaramine ligand in
AH3 and AH7 that introduces a greater steric hindrance. It
is not however clear why transplatin is found to have a
lower molar conductivity value than cisplatin. It should
however be noted that 1:1 mixture of DMF and water does
not truly represent biological fluids such as extracellular
Table 1: Composition of AH3 and AH7
AH3 AH7
Calculated % Observed % Calculated% Observed %
C 15.9 16.5 ± 0.4 15.3 15.1 ± 0.4
H 2.1 2.2 ± 0.4 2.6 2.3 ± 0.4
N 7.4 7.1 ± 0.4 14.3 13.8 ± 0.4
Cl 18.8 18.6 ± 0.3 18.1 18.3 ± 0.3
Pt 51.6 50.8 ± 1.0 49.8 49.9 ± 1.0
Structures of AH3 and AH7 Figure 1
Structures of AH3 and AH7.
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and intracellular fluids where the degree of dissociation is
expected to be higher because of a higher water content.
IR and Raman spectral analyses
The prominent bands observed in the IR and Raman spec-
tra of AH3 and AH7 are given in Table 2.
AH3
IR
The broad band at 3309 cm-1 is believed due to O-H and
N-H stretching vibrations. The band at 3062 cm-1  is
believed to be due to C-H stretch. The bands at 1649 and
1595 cm-1 are due to N-H bending vibrations whereas that
at 1444 cm-1 is due to C-H bending vibration. The band at
1496 cm-1 is due to 'aromatic' ring stretch. The band at
1281 cm-1 is due to O-H bending vibration. The bands at
1213 and 1105 cm-1 are due to C-O stretching vibrations.
The band at 1028 cm-1 is due to ring stretch. The bands at
687 and 798 cm-1 are due to C-H out of plane bending
vibrations. The band at 879 cm-1 is believed due to N-H
wagging. The bands at 580, 546 and 432 cm-1 are due to
Pt-N stretching vibrations.
Raman
The band at 3076 cm-1 is believed due to N-H stretching
vibration whereas that at 2467 cm-1 and is believed to be
due to C-H stretching vibration. The band at 2307 cm-1 is
believed to be associated with the vibration of 2-hydrox-
ypyridine ring. The band at 1603 cm-1 is due to N-H bend-
ing vibration whereas the bands at 1067, 1030 and 664
cm-1 are due to C-H in plane bending of the heterocyclic
ring. The band at 866 cm-1 is due to N-H wagging. The
band at 519 cm-1 is due to Pt-N(NH3) stretching vibration
and that at 330 cm-1 is due to Pt-Cl stretching vibration.
The band at 243 cm-1 is due to Pt-N(3-hydroxypyridine)
stretch whereas that at 122 cm-1 is due Pt-N bending vibra-
tion. The band at 76 cm-1 is associated with the lattice
mode.
AH7
The band at 3192 is due to N-H and C-H stretching vibra-
tions. The band at 1614 cm-1 is due to N-H bending vibra-
tion whereas that at 1539 cm-1 is due to aromatic ring
stretch. The band at 1371 is due to C-H bending vibration.
The band at 1302 cm-1 is due to in-plane deformation of
the heterocyclic ring whereas that at 777 cm-1 is due to its
out-of-pane deformation. The band at 496 cm-1 is due to
Pt-N stretching vibration.
Raman
The band at 3562 and 3314 are believed due to N-H
stretching vibration whereas that 2806 is believed to be
due to C-H stretching vibration. The band at 2361 cm-1 is
believed to be associated with the vibration of pyridine
ring. The band at 1537 cm-1 is due to N-H bending vibra-
tion whereas the band at 1030 cm-1 is due to C-H in-plane
bending of the heterocyclic ring. The band at 346 cm-1 is
due Pt-Cl stretch. The band at 95 cm-1 is due to bending
vibration of the pyridine ring.
Mass 1H and NMR spectral analyses
The prominent peaks observed in the EIS mass and 1H
NMR spectra of AH3 and AH7 are given in table 3.
Mass
AH3
The mass spectrum of AH3 has a peak with m/z = 876 cor-
responding to (ClPt-µ-(NH)Pt(Cl)(3-hydroxypyridine)-
µ-(NH)Pt(3-hydroxypyridine) that is believed to be
formed in situ from joining of the fragments produced
from AH3. The peak with m/z = 516 corresponds to
(NH2)2Pt-µ-(NH)Pt(pyridine) that is also believed to be
formed in situ from joining of the fragments produced
from AH3. The peak with m/z = 357 corresponds to (M -
OH - 4H) and that with m/z = 384 corresponds to (M -
NH3 - 2Cl + 3-hydroxypyridine - H).
AH7
The mass spectrum of AH3 has a peak with m/z = 516 cor-
responding to (PtCl(2,3-diaminopyridine) that is
believed to be formed in situ from joining of the frag-
ments produced from AH3. The peak with m/z = 438 cor-
responds to (M - Cl + 2,3-diaminopyridine) that is also
believed to be formed in situ from joining of the frag-
ments produced from AH3. The peak with m/z = 360 cor-
responds to (M - H -NH3) and that with m/z = 265
corresponds to (M - Cl - (2,3-diaminoyridine) + NH3).
Plots of molar conductivities against concentrations as  applied to AH3, AH7, cisplatin and transplatin Figure 2
Plots of molar conductivities against concentrations as 
applied to AH3, AH7, cisplatin and transplatin.
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1H NMR
AH3 [See Additional file 1]
The resonance at δ = 10.80 ppm is due to OH proton, that
at 8.42 ppm is due to CH that lies in between the nitrogen
centre and the carbon to which OH group is attached. The
resonance at δ = 8.14 ppm is due to CH at the other ortho
position and that at δ = 8.03 ppm is due to CH at the para
position. The resonance at δ = 8.02 ppm is due to CH at
the meta position. The resonances at δ = 4.30 and 3.86
ppm are due to NH-Pt. The resonance δ = 3.34 ppm is due
to water and that 2.50 is due to DMSO.
AH7 [See Additional file 2]
The resonances at δ = 7.30, 7.20 and 6.90 ppm are due to
CH. The resonance at 4.02 ppm is due to NH-Pt, that at
3.34 is due to water and that at 2.50 is due to DMSO. The
resonances at δ = 2.70 and 2.40 ppm are due to NH.
Interaction with pBR322 plasmid DNA
Figure 3 gives the electrophoretograms applying to the
interaction of pBR322 plasmid DNA with cisplatin, trans-
platin, AH3 and AH7 at concentrations ranging from 1
µM to 10 µM in the case of cisplatin and transplatin and 5
µM to 50 µM in the case of AH3 and AH7.
Figure 3 here
As pBR322 plasmid DNA, which is found to be a mixture
of mainly supercoiled form I and a small amount of singly
nicked circular form II, is interacted with increasing con-
centrations of AH3, the mobility of both form I and form
II bands changes such that the two bands co-migrate for
the concentrations of AH3 ranging from 30 to 40 µM
above which the two bands partially separate. There is
also a decrease in intensity of the bands at higher concen-
trations of AH3. The change in mobility of the form I
band is due to a change in its conformation brought about
by covalent binding of AH3 with the DNA. AH3 is
expected to form mainly monofunctional Pt-G and intras-
trand bifunctional Pt(GG) adducts with DNA, the latter
causing the bending of a DNA strand mainly at the bind-
ing site. The decrease in intensity of the bands is due to
DNA damage brought about possibly by the stacking
interaction between 3-hydroxypyridine ligand in AH3 and
nucleobases in DNA. The sharp increase in intensity of
form II band at low concentrations of AH3 as compared
to that in untreated DNA indicates the conversion of some
of form I DNA to form II DNA due catalyzed by AH3.
When pBR322 plasmid DNA is interacted with increasing
concentrations of AH7 also, there is an initial increase in
intensity of the form II band at low concentrations of the
compound, indicating the conversion of some of form I
DNA to form II DNA as in the case of AH3. The mobility
of both forms I and II bands appear to remain unchanged
with the change in concentration of AH7. The results sug-
gest that AH7 is less able to cause conformational change
in pBR322 plasmid DNA than AH3. It may be noted that
the presence of two amine groups in 2,3-diaminopyridine
makes it slightly bulkier than 3-hydroxypyridine. As a
result, steric constraint hindering access to platinum
would be greater in AH7 than AH3. As discussed earlier,
2,3-diaminopyridine and 3-hydroxypyridine are also
expected to differ in their polarity. This factor too may
have some influence on the reactivity of AH3 and AH7
and their binding with DNA.
BamH1 digestion
Figure 4 shows the electrophoretograms for the incubated
mixtures of pBR322 plasmid DNA and varying concentra-
tions of cisplatin and transplatin, AH3 and AH7, followed
by BamH1 digestion. For cisplatin and transplatin, con-
centration ranges from 0 to 10 µM and for AH3 and AH7
it ranges from 0 to 50 µM. In the absence of platinum
compounds, only the linear form III band is observed,
indicating that all of the pBR322 plasmid DNA is doubly
nicked by BamH1 at the specific GG site. At low concen-
trations of AH3 (0 to 20 µM), only form III band is
observed whereas at higher concentrations of the com-
pound (25 µM to 50 µM) a mixture of forms I, II and III
bands are observed. At the lowest concentration of AH7 (5
µM), a mixture of forms I, II and III is observed and at
higher concentrations (10 µM or greater), a mixture of
Table 2: Prominent IR Raman spectral bands observed in AH3 and AH7 (ν cm-1)
IR (cm-1)R a m a n
AH3 3309 (s, NH and OH), 3062 (w, CH), 1649(w, NH), 1595 (s, 
'aromatic ring'), 1444 (s, 'aromatic ring'), 1281 (s, OH), 1213 (w, 
CO), 1105 (w, CO), 1028 (ring stretch), 798 (m, CH), 687 (m, 
CH), 580 (w, Pt-N), 546 (m, Pt-N), 514 (m, Pt-N), 432 (m, pyridine 
ring)
3076 (m, NH), 2467 (m br, CH) 1603 (w, NH), 1030 (s, CH), 866 
(m, CH), 664 (w, pyridine ring), 519 (w, Pt-N(NH3)), 330 (m, Pt-
N(3-hydroxypyridine)), 243 (w, Pt-N(2-hydroxypyridine)), 122 (s, 
Pt-N), 81 (m, lattice)
AH7 3192 (s br, NH and CH stretch), 1614 (m, NH bending), 1539 (s, 
aromatic ring stretch), 1371 (m, CH bending), 1302 (s, ring in-
plane deformation), 1211 (m, CH in-plane bending of heterocyclic 
ring), 777 (w d, ring out-of-plane deformation), 496 (w, Pt-N 
stretch)
3562 (w, NH stretch), 3314 (s, NH stretch), 2806 (m, CH stretch), 
2361 (m, ring stretch), 1537 (m, NH bending), 1030 (s, CH in-
plane bending), 797 (m, ring out-of-plane deformation), 346 (m, Pt-
Cl stretch), 95 (m, ring bending)
The letters 's', 'm', 'w', 'd' and 'br' stand for 'strong', 'medium', 'weak', 'doublet' and 'broad' respectively.BMC Chemical Biology 2006, 6:3 http://www.biomedcentral.com/1472-6769/6/3
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forms I and II is observed. The results suggest that AH7 is
able to cause a greater conformational change to the DNA
than AH3, but as noted earlier, AH3 causes a greater
change in mobility of pBR322 plasmid DNA than AH7.
A mixture of forms I, II and III bands are observed for all
concentrations of cisplatin ranging from 1 to 10 µM with
forms I and II bands being the faintest at 1 µM cisplatin
and form III band being the faintest at 10 µM cisplatin.
The results indicate increasing prevention of BamH1
digestion with the increase in concentration of cisplatin.
This is due to conformational change in the DNA brought
about by the covalent binding of cisplatin with the DNA
(mainly intrastrand GG). A mixture of forms I, II and III
was also observed for all concentrations of transplatin
indicating that transplatin is also able to prevent BamH1
digestion. However, the relative intensities of the three
bands suggest that transplatin is less able to prevent
BamH1 digestion than cisplatin. Like cisplatin transplatin
can form monofunctional adducts but unlike cisplatin
(which forms intrastrand bifunctional adducts), transpla-
tin is more likely to form interstrand bifunctional adducts.
The results suggest that the formation of interstrand
adducts also brings about sufficient conformational
change in DNA (so as to prevent BamH1 digestion)
mainly due to mismatch between interbase distance and
that between the two trans arms of transplatin. The pro-
gressive decrease in intensity of the bands from lanes 9 to
13 appears to be artefact as the band applying to untreated
and undigested DNA (lane 13) could not be seen.
Cytotoxicity
Table 4 gives the IC50 values of AH3, AH7 and cisplatin
against the cell lines: A2780, A2780cisR and A2780ZD047R.
It can be seen that both AH3 and AH7 are significantly less
active than cisplatin against the cell lines: A2780,
A2780cisR and A2780ZD0473R. It should however be noted
the IC50 value for cisplatin found in the present study for
the cell line A2780 is significantly higher than the
reported value [24]. This difference may be the result of
some problems faced in growing A2780 cells in the
present study. It is thus possible that the underestimation
of activity may apply to AH3 and AH7 so that the actual
IC50 value of AH3 and AH7 for the cell line A2780 could
be significantly lower than the value found.
The other point to note is that although AH3 and AH7 are
less active than cisplatin, the change in activity of the com-
pound in going from cisplatin-responsive cell line: A2780
to the resistant cell lines: A2780cisR and A2780ZD0473R is
less marked than that for cisplatin, The results suggest that
at the level of their activity the compounds have been able
to overcome mechanisms of resistance operating in
A2780cisR and A2780ZD0473R cell lines. As stated earlier,
like cisplatin AH3 and AH7 are expected to form mono-
functional and intrastrand bifunctional adducts with
DNA. It is possible that the presence of a bulky planara-
mine ligand makes AH3 and AH7 much less reactive than
cisplatin. Also, some AH3 and AH7 molecules may simply
undergo intercalation with DNA or while binding cova-
lently with nucleobases in DNA may undergo stacking
interaction. Damage to pBR322 plasmid DNA caused by
AH3 and AH7 (discussed earlier) may be due to intercala-
tion.
AH3 is found to be more active than AH7 against the three
cell lines. It should be recalled that molar conductivity
value of AH7 is found to be higher than that for AH3. The
presence of two amino groups in 2,3-diaminopyridine lig-
and make AH7 more ionisable than AH3 in which the
planaramine is 3-hydroxypridine. It is possible that both
the cell uptake and level of binding with DNA will be for
AH7 than AH3 which would explain the lower activity of
AH7 than AH3.
Conclusion
Two  cis-planaramineplatinum(II) complexes: cis-(3-
hydroxypyridine)(ammine)dichloroplatinum(II) (code
named AH3) and cis-(2,3-diaminopyrid-
ine)(ammine)dichloroplatinum(II) (code named AH7)
have prepared and characterised based on elemental anal-
yses, IR, Raman, mass and 1H NMR spectral measure-
ments. The interaction of the compounds with pBR322
Table 3: Prominent peaks observed in the ESI mass and 1H NMR spectra of AH3 and AH7
ESI Mass 1H NMR
AH3 MM = 378.1 EIS-MS (DMF) (ClPt-µ-(NH)Pt(Cl)(3-hydroxypyridine)-µ-
(NH)Pt(3-hydroxypyridine) = 876 (0.57); (NH2)2Pt-µ-
(NH)Pt(pyridine) = 516 (0.98); (M - OH - 4H) = 357 (0.11); (M 
- NH3 - 2Cl + 3-hydroxypyridine - H) = 384 (1.00)
1 H NMR DMSO δ ppm: 10.80 (s br, due to OH); 8.42 (d, due 
to CH ortho); 8.14 (d, due to CH ortho); 8.03 (d, due to CH 
para); 8.02 (quartet, due to CH meta); 4.30 (s, due to NH-Pt); 
3.86 (s, NH-Pt); 3.34 (s, due to water); 2.50 (due to DMSO)
AH7 MM = 392.1 EIS-MS (DMF) (PtCl(2,3-diaminopyridine) = 516 (0.36); (M - Cl 
+ 2,3-diaminopyridine) = 438 (1.00); (M - H) = 377 (0.09); (M - 
H -NH3) = 360; (M - Cl - NH3 - H) = 324 (0.66); (M - Cl - (2,3-
diaminoyridine) + NH3) = 265 (0.31)).
1H NMR DMSO δ ppm: 7.30 (due to CH); 7.20 (due to CH); 
6.90 (due to CH); 4.02 (s; NH-Pt); 3.34 (d, due to water); 2.70 
(NH), 2.50 (due to DMSO), 2.40 (s, NH))
The letters 's', 'm', 'w', 'd' and 'br' stand for 'strong', 'medium', 'weak', 'doublet' and 'broad' respectively.BMC Chemical Biology 2006, 6:3 http://www.biomedcentral.com/1472-6769/6/3
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plasmid DNA has been studied and the activity of the
compound against ovarian cell lines: A2780, A2780cisR
and A2780ZD0473R have also been determined where cispl-
atin has been used as the reference. Like cisplatin, AH3
and AH7 are expected to form monofunctional and intras-
trand bifunctional adducts with DNA, but the compounds
are found to cause a weaker unwinding of supercoiled
form I pBR322 plasmid DNA and the prevention of
BamH1 digestion. The lower activity of AH3 and AH7 as
compared to cisplatin is believed to be due to their
reduced ability to bind with DNA because of a greater
steric constraint introduced by bulkier planaramine lig-
ands. AH3 is found to be more active than AH7 against
the three cell lines. It is believed that the presence of two
amino groups in 2,3-diaminopyridine ligand make AH7
more ionisable than AH3 in which the planaramine is 3-
hydroxypridine. It is possible that both the cell uptake and
level of binding with DNA will be for AH7 than AH3
which would explain the lower activity of AH7 than AH3.
The determination of cell uptake and the level of binding
with DNA would indicate whether the idea is true or not.
Methods
Materials
Potassium tetrachloroplatinate (K2  [PtCl4]), 2,3-diami-
nopyridine [C7H7N2], N, N-dimethylformamide [DMF]
[C3H7NO], 3-hydroxypyridine, cisplatin and transplatin
were obtained from Sigma Aldrich Chemical Company
Milwaukee USA; acetone [(CH3)2CO] and silver nitrate
[AgNO3] were obtained from Ajax Chemicals Auburn
NSW Australia; methanol [CH3OH] and ethanol
[C2H5OH] were obtained from Merck Pty. Limited Kilsyth
VIC Australia. pBR322 plasmid DNA was obtained from
ICN Biochemicals Ohio USA.
Syntheses
cis-planaramineplatinum(II) complexes: cis-(3-hydrox-
ypyridine)(ammine)dichloroplatinum(II) (code named
AH3) and cis-(2,3-diaminopyridine)(ammine)dichloro-
platinum(II) (code named AH7) have synthesized accord-
ing to modified Dhara [17] method.
cis-Pt(NH3)(3-hydroxypyridine)Cl2 (AH3)
415 mg (1 mmol) of K2 [PtCl4] was dissolved in 10 mL of
milli Q (mQ) water to which was added 2 g (about 12
(A): Interaction of pBR322 plasmid DNA with increasing concentrations of cisplatin (lanes 0–4: 1: 1 µM; 2: 2.5 µM; 3: 5 µM; 4:  10 µM.) and transplatin (lanes 7–13: 7: 0 8: 1 µM; 9: 2.5 µM; 10: 5 µM; 11: 10 µM, 13: 0.) ranging from 1 to 10 µM Figure 3
(A): Interaction of pBR322 plasmid DNA with increasing concentrations of cisplatin (lanes 0–4: 1: 1 µM; 2: 2.5 µM; 3: 5 µM; 4: 
10 µM.) and transplatin (lanes 7–13: 7: 0 8: 1 µM; 9: 2.5 µM; 10: 5 µM; 11: 10 µM, 13: 0.) ranging from 1 to 10 µM. (B): Inter-
action between pBR322 plasmid DNA and increasing concentrations of AH3 and AH7 ranging from 5 µM to 50 µM: (Lanes 0 
to 10: lane 0: untreated plasmid, 1:5 µM; 2: 10 µM; 3: 15 µM; 4: 20 µM; 5: 25 µM; 6: 30 µM; 7: 35 µM; 8: 40 µM; 9: 45 µM; 10: 
50 µM).
 0   1  2  3  4       7  8  9  10 11    13 
      ( A)
0 1 23456789 1 0
AH3
0 123 456 7 891 0
AH7
(B)BMC Chemical Biology 2006, 6:3 http://www.biomedcentral.com/1472-6769/6/3
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mmol) of KI. The mixture was stirred at room temperature
for 5 min. 0.14 mL (1 mmol) of 1:1 aqueous solution of
ammonia was added to the mixture with stirring that was
kept in ice for about 30 min. The yellow precipitate of cis-
Pt(NH3)I3  formed immediately after the addition of
ammonia solution. 95 mg (1 mmol) of 3-hydroxypyrid-
ine, dissolved in 5 mL of mQ water by sonification, was
added with stirring to the mixture that was kept in ice. The
colour of the precipitate changed from yellow to brown
after about 15 min at the end of which the precipitate of
cis-Pt(3-hydroxypyridine)(NH3)I2 was collected by filtra-
tion, washed with ice-cold water and air-dried. [The time
was found to be critical as longer period resulted in the
formation of some cis-bis[(3-hydroxypyridine)]I2Pt(II).]
The mass of the precipitate was 301 mg (0.5 mmol). The
precipitate was suspended in 5 mL of mQ water to which
was added 168 mg (0.99 mmol) of AgNO3 with stirring in
the dark at room temperature. Stirring was continued for
3 h. The mixture was centrifuged to collect the yellow
supernatant to which was added 80 mg (1.05 mmol) of
KCl with stirring at room temperature. Stirring was con-
tinued for 24 h. The yellow precipitate of cis-Pt(3-hydrox-
ypyridine)(NH3)Cl2 was collected by filtration, washed
with mQ water and air-dried. The weight of the final prod-
uct was 140 mg (0.4 mmol) corresponding to 40% yield.
It was characterized by elemental analyses, IR, Raman,
mass and 1H NMR spectral studies.
cis-(2,3-diaminopyridine)(ammine)dichloroplatinum(II) 
(AH7)
415 mg (1 mmol) of K2 [PtCl4] was dissolved in 20 mL of
mQ water to was added 4 g (about 24 mmol) of KI. The
mixture was stirred at room temperature for 5 min. 0.14
mL (1 mmol) of 1:1 aqueous solution of ammonia was
added to the mixture with stirring that was continued for
about 30 min. 109 mg (1 mmol) of 2,3-diaminopyridine
was added with stirring to the mixture at room tempera-
ture. Dark green precipitate of cis-Pt(2,3-diaminopyrid-
ine)(NH3)I2 formed immediately. Stirring was continued
for 24 h at room temperature. The precipitate was col-
(A): Electrophoretogram for the incubated mixtures of pBR322 plasmid DNA and varying concentrations of cisplatin (lanes 0– 5: 0: untreated plasmid; 1: 0, 2: 1 µM; 3: 2.5 µM; 4: 5 µM; 5: 10 µM) and transplatin (lanes 7–13: 7: untreated plasmid; 8: 0, 9: 1  µM; 10: 2.5 µM; 11: 5 µM; 12: 10 µM) Figure 4
(A): Electrophoretogram for the incubated mixtures of pBR322 plasmid DNA and varying concentrations of cisplatin (lanes 0–
5: 0: untreated plasmid; 1: 0, 2: 1 µM; 3: 2.5 µM; 4: 5 µM; 5: 10 µM) and transplatin (lanes 7–13: 7: untreated plasmid; 8: 0, 9: 1 
µM; 10: 2.5 µM; 11: 5 µM; 12: 10 µM) (B): Electrophoretogram for the incubated mixtures of pBR322 plasmid DNA and vary-
ing concentrations of: AH3 and AH7 (lane 0: untreated and undigested DNA, lane 1: 5 µM, lane 2: 10, lane 3: 15 µM, lane 4: 20 
µM, lane 5: 25 µM, lane 6: 30 µM, lane 7: 35 µM, lane 8: 40 µM, lane 9: 45 µM, lane 10: 50 µM) followed by digestion with 
BamH1. Lane B applies to untreated but digested pBR322 plasmid DNA.
    0   1  2 3   4   5 7    8  9 10 11 13
(A)
0    1   2  3 4 5    6   7   8  9    10 0 0    1   2  3 4 5    6   7   8  9    10 0
0    1 2   3  4 5   6  7   8  9  10  0 0    1 2   3  4 5   6  7   8  9  10  0
AH3 AH7
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lected by filtration, washed with ice-cold water and etha-
nol, and air-dried. The mass of the precipitate was 454 mg
(0.8 mmol). The precipitate was suspended in 5 mL of
mQ water to which was added 266 mg (1.57 mmol) of
AgNO3 with stirring in the dark at room temperature. Stir-
ring was continued for 10 h. The mixture was centrifuged
to collect the black supernatant to which was added 125
mg (1.68 mmol) of KCl with stirring at room temperature
that was continued for 24 h. The black precipitate of cis-
Pt(2,3-diaminopyridine)(NH3)Cl2 was collected by filtra-
tion, washed with ice cold water and air-dried. The weight
of the final product was 40 mg (0.1 mmol) corresponding
to 10% yield. It was characterized by elemental analyses,
IR, Raman, mass and 1H NMR spectral studies.
Characterization
C, H, N and Cl were determined using the facility at the
Australian National University. Platinum was determined
by graphite furnace atomic absorption spectroscopy
(AAS) using the Varian Spectraa-20 Atomic Absorption
Spectrophotometer. Infrared spectra were collected using
a Bruker IFS66 spectrometer equipped with a Spectra-Tech
Diffuse Reflectance Accessory (DRA), an air-cooled DTGS
detector, a KBr beamsplitter with a spectral range of 4000
to 400 cm-1. The instrument was run under a vacuum dur-
ing spectral acquisition. Spectra were recorded at a resolu-
tion of 4 cm-1, with the co-addition of 128 scans and a
Blackman-Harris 3-Term apodisation function was
applied. Prior to analysis the samples were mixed, and
lightly ground, with finely ground spectroscopic grade
KBr. The spectra were then manipulated using the
Kubelka-Munk mathematical function in the OPUS™ soft-
ware to convert the spectra from reflectance into absorb-
ance. Raman spectra were collected using a Bruker RFS100
Raman spectrometer equipped with an air cooled Nd:YAG
laser emitting at a wavelength of 1064 nm, and a liquid
nitrogen cooled germanium detector with an extended
spectral band range of 3500 to 50 cm-1. 180° sampling
geometry was employed. Spectra were recorded at a reso-
lution of 4 cm-1, with the co-addition of 100 scans at a
laser power of 0.065 mW. A Blackman-Harris 4-Term apo-
disation function was applied and the spectra were not
corrected for instrument response. To obtain mass spectra,
solution of AH3 and AH7, made in 10% DMF and 90%
methanol, were sprayed into a Finnigan LCQ ion trap
mass spectrometer in which fragmentation was produced
by a high energy electron beam bombardment. 1H NMR
spectra of AH3 and AH7 were recorded in dimethylsulfox-
ide-d6 (DMSO-d6) solution in a Bruker AVANCE DPX 400
spectrometer. Spectra were referenced to internal solvent
residues and were recorded at 300 K (± 1 K).
Molar conductivity
The molar conductivity values for AH3, AH7, cisplatin
and transplatin were determined using PW9506 digital
conductivity meter available at the School of Chemistry,
University of Sydney. The compounds were dissolved in
1:1 mixture of DMF and water. The measurements were
done at concentrations: 1 mM, 0.5 mM, 0.2 mM and 0.05
mM. The molar conductivity (Λm) was calculated as Λm=
k/c where k is specific conductivity and c is the concentra-
tion [18]. The molar conductivity values were plotted
against concentration and the curve was extrapolated to
zero concentration to obtain the limiting value.
Interaction with pBR322 plasmid DNA
Interaction of AH3, AH7 and cisplatin with pBR322 plas-
mid DNA was studied by agarose gel electrophoresis. The
method used was a modification of that described by
Stellwagen [19]. Briefly, solutions of pBR322 plasmid
DNA (at concentration 0.5 µg mL-1) were incubated with
increasing concentrations of compounds ranging from 4
µM to 50 µM in a shaking water bath at 37°C for 4 h, fol-
lowing which 16 µL aliquots of drug-DNA mixtures con-
taining 0.6 µg of DNA was loaded onto the 1% gel and
electrophoresis was carried under TAE buffer for 2 h at 5 V
cm-1. The gel was stained in the same buffer containing
ethidium bromide (0.5 mg mL-1) and visualised under UV
light using the Bio-Rad Trans illuminator IEC 1010. The
illuminated gel was photographed with a Polaroid camera
(a red filter and Polaroid type of film was used).
BamH1 digestion
BamH1 is known to recognize the sequence G/GATCC
and hydrolyse the phosphodiester bond between adjacent
guanine sites [20]. BamH1 contains a single restriction
site for pBR322 plasmid DNA and is thus able to convert
the DNA from supercoiled form I and singly nicked circu-
Table 4: IC50 value and resistance factors for AH3, AH7 and cisplatin against the cell lines: A2780, A2780cisR and A2780ZD047R.
A2780 A2780-cisR IC50A2780cisR/IC50A2780 A2780ZD0473R
IC50 IC50 RF IC50
AH3 3.8 ± 1.0 6.9 ± 1.0 1.8 7.5 ± 1.0
AH7 11.7 ± 1.4 8.5 ± 1.3 0.7 10.6 ± 1.0
Cisplatin 1.1 ± 0.4 2.3 ± 0.4 2.1 2.2 ± 0.4
The letters 's', 'm', 'w', 'd' and 'br' stand for 'strong', 'medium', 'weak', 'doublet' and 'broad' respectively.BMC Chemical Biology 2006, 6:3 http://www.biomedcentral.com/1472-6769/6/3
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lar form II to linear form III DNA [21]. In this experiment,
a same set of drug-DNA mixtures as that described previ-
ously, was first incubated for 4 h in a shaking water bath
at 37°C and then subjected to BamH1 (10 units µL-1)
digestion. To each 20 µL of incubated drug-DNA mixtures
were added 3 µL of 10× digestion SB buffer followed by
the addition of 0.2 µL BamH1 (2 units). The mixtures
were left in a shaking water bath at 37°C for 1 h at the end
of which the reaction was terminated by rapid cooling.
The gel was subsequently stained with ethidium bromide,
visualized under UV light and photographed as described
previously.
List of abbreviations
AH6:  cis-bis(imidazo(1,2-α)pyridine)dichloroplati-
num(II). Cisplatin: cis-dichlorodiamminplatinum(II).
Transplatin:  trans-dichlorodiamminplatinum(II). 1×TAE
buffer: 0.05 M Tris base + 0.05 M glacial acetic acid + 1
mM EDTA, pH = 8.0. DMSO: Dimethyl sulfoxide. AAS:
Atomic absorption spectrophotometry. A: Adenine. G:
Guanine
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1H NMR spectrum of AH3. This figure gives the 1H NMR spectrum of 
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1H NMR spectrum of AH7. This figure gives the 1H NMR spectrum of 
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